C
Charles M. Perou
Researcher at University of North Carolina at Chapel Hill
Publications - 645
Citations - 235604
Charles M. Perou is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 156, co-authored 573 publications receiving 202951 citations. Previous affiliations of Charles M. Perou include North Carolina Central University & University of Chicago.
Papers
More filters
Journal ArticleDOI
Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases
Shuying Liu,Makiko Umezu-Goto,Mandi M. Murph,Yiling Lu,Wenbin Liu,Fan Zhang,Shuangxing Yu,L. Clifton Stephens,Xiaojiang Cui,George Murrow,Kevin R. Coombes,William J. Muller,Mien Chie Hung,Charles M. Perou,Adrian V. Lee,Xianjun Fang,Gordon B. Mills +16 more
TL;DR: It is demonstrated that expression of ATX or each edg family LPA receptor in mammary epithelium of transgenic mice is sufficient to induce a high frequency of late-onset, estrogen receptor (ER)-positive, invasive, and metastatic mammary cancer.
Journal ArticleDOI
Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer
Dezheng Huo,Francis Ikpatt,Andrey Khramtsov,Jean Marie Dangou,Rita Nanda,James J. Dignam,Bifeng Zhang,Tatyana A. Grushko,Chunling Zhang,Olayiwola Oluwasola,David Malaka,Sani Malami,Abayomi Odetunde,Adewumi O. Adeoye,Festus Iyare,Adeyinka G. Falusi,Charles M. Perou,Olufunmilayo I. Olopade +17 more
TL;DR: The distribution of molecular subtypes of invasive breast tumors in indigenous black women in West Africa underscores the urgent need for research into the etiology and treatment of the aggressive molecular sub types that disproportionately affect young women in the African diaspora.
Journal ArticleDOI
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer.
Britta Weigelt,Zhiyuan Hu,Xiaping He,Chad A. Livasy,Lisa A. Carey,Matthew G. Ewend,Annuska M. Glas,Charles M. Perou,Laura J. van't Veer +8 more
TL;DR: The results suggest that the capacity to metastasize is an inherent feature of most breast cancers and imply that poor prognosis breast carcinomas classified either by the intrinsic gene set or the 70 prognosis genes represent distinct disease entities that seem sustained throughout the metastatic process.
Journal ArticleDOI
Estrogen-Regulated Genes Predict Survival in Hormone Receptor–Positive Breast Cancers
Daniel S. Oh,Melissa A. Troester,Jerry Usary,Zhiyuan Hu,Xiaping He,Cheng Fan,Junyuan Wu,Lisa A. Carey,Charles M. Perou +8 more
TL;DR: This study provides new biologic information concerning differences within hormone receptor-positive breast cancers and a means of predicting long-term outcomes in tamoxifen-treated patients.
Journal ArticleDOI
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
Brett Wallden,James Storhoff,Torsten O. Nielsen,Naeem Dowidar,Carl Schaper,Sean Ferree,Shuzhen Liu,Samuel Leung,Gary K. Geiss,Jacqueline E. Snider,Tammi L. Vickery,Sherri R. Davies,Elaine R. Mardis,Michael Gnant,Ivana Sestak,Matthew J. Ellis,Charles M. Perou,Philip S. Bernard,Joel S. Parker +18 more
TL;DR: The results show that the FDA-cleared and CE marked Prosigna test provides an accurate estimate of the risk of distant recurrence in hormone receptor positive breast cancer and is also capable of identifying a tumor's intrinsic subtype that is consistent with the previously published PCR-based PAM50 assay.